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AHRF = acute hypoxemic respiratory failure 
 
ARDS = acute respiratory distress syndrome 
 
BiPAP = bilevel positive airway pressure 
 
COVID-19 = Coronavirus disease 2019 
 
CPAP = continuous positive airway pressure 
 
HFNC = High flow nasal cannula 
 
NIPPV = non-invasive positive pressure ventilation 
 
OR = odds ratio 
 











Much of the debate around the Coronavirus disease 2019 (COVID-19) pandemic in the 
popular press has focused on invasive (via endotracheal tube or tracheostomy) ventilation of 
severely sick patients and potential ventilator shortages. Amid increasing concerns of medical 
professionals about the harms associated with invasive ventilation, there is interest to explore 
the role of non-invasive positive pressure ventilation (NIPPV) in the treatment of acute 
hypoxemic respiratory failure (AHRF) and acute respiratory distress syndrome (ARDS) due 
to COVID-19.  In this commentary we aim to summarize what is known about the role of 
NIPPV in patients with AHRF and ARDS due to COVID-19 and other viral infections, point 
out evidence gaps and make a case for consideration of NIPVV as a possible alternative to 
early intubation in patients with COVID-19. 
 
Aims to limit intubations are mainly based on concer s about ventilator-induced lung injury 
and the recognition that the pathophysiological and atomical features of COVID-19 related 
lung infection are different from classic ARDS, forwhich invasive mechanical ventilation is 
considered the standard of care. COVID-19 is primarily causing injury to the capillary 
endothelium instead of essential injury to the alveolar epithelium.1 Lungs affected by 
COVID-19 show marked ventilation-perfusion mismatch but preserved compliance,2 making 
the recruitment maneuver and the use of high positive end-expiratory pressure potentially 
deleterious. The risk of ventilator-induced lung injury in patients with COVID-19 is further 
increased by the lack of specialized personnel (e.g. shortage in respiratory therapists and 
intensivists) and the lack of appropriate equipment ( . g. use of devices used for chronic 











NIPPV includes treatment with continuous positive airw y pressure (CPAP) and bilevel 
positive airway pressure (BiPAP).3 CPAP is useful in AHRF, as it recruits collapsed alveoli, 
improves ventilation-perfusion matching, and therefo  oxygenation. BiPAP is useful for the 
treatment of hypercapnic respiratory failure, as it supports ventilation by using a different 
level of in-and expiratory continuous airway pressure, thus increasing tidal volume and 
minute ventilation. Patients with COVID-19 pneumonia and ARDS typically have severe 
hypoxemia and relatively well preserved lung mechanics.2 It is therefore reasonable to 
assume that patients with COVID-19 will benefit from CPAP therapy. However, as many 
patients with COVID-19 and severe respiratory failure are obese and may therefore have risk 
factors for hypercapnia including obstructive sleep apnea and obesity hypoventilation 
syndrome, BiPAP therapy should be considered on a case-by-case basis. 
 
Guideline recommendations 
Guideline recommendations on the use of NIPPV in COVID-19 vary widely (Table 1).4-11 
COVID-19 guidelines of the American Thoracic Society9 and the Infectious Diseases Society 
of America10 focus primarily on pharmacologic interventions and make no mention of 
NIPPV. The majority of organizations including the National Institutes of Health,7 the 
Society of Critical Care Medicine/ European Society of Intensive Care Medicine Surviving 
Sepsis Campaign,4 the  English National Health Service,5 the Italian Thoracic Society and the 
Italian Respiratory Society,6 as well as the World Health Organization8 support the use of 
NIPPV in patients with COVID-19 and AHRF, at least in certain circumstances. For the 
World Health Organization, this constitutes a change i  policy compared with earlier during 
the pandemic. In contrast, the Australian and New Zaland Intensive Care Society 
recommend against the use of NIPPV in patients withCOVID-19 in favor of early 










harms of NIPPV in patients with COVID-19 and concerns that the aerosol produced by the 
use of NIPPV poses an increased infection risk for health care professionals.12  
 
Prone positioning 
Prone positioning has been shown to reduce mortality in severe ARDS.13 There is emerging 
evidence that prone positioning is beneficial in patients with ARDS due to COVID-19, and 
that NIPPV can be provided to these patients in the prone position in a general ward.14 
 
What are the benefits and harms of NIPPV compared with early intubation in COVID-
19?  
NIPPV has been widely used in China and some European countries during the current 
pandemic, but to date there is insufficient evidence to support this use.  
An Italian retrospective chart review study of patien s with COVID-19 found that of 71 
patients on helmet CPAP, 26 (37%) were intubated and 54 (76%) died (before or after 
intubation). The availability of ventilators was limited in the study setting, thus not allowing 
for a comparison between CPAP use and early intubation.  
 
NIPPV was commonly used during the severe acute respiratory syndrome (SARS) epidemic 
in China that emerged in 2002, but only four small observational studies that mention NIPPV 
are available,17 one of which focused on the nosocomial infection rsk and included only two 
patients on BiPAP.18 Another study did not specify the ventilation type that was used and did 
not evaluate outcomes in patients on NIPPV.19 In the two remaining studies, both from Hong 
Kong, BiPAP treatment was used in all patients on NIPPV.20,21 Intubation was avoided in 14 
out of 20 (70%) patients on BiPAP and  was associated with a shorter ICU stay (3.1 days vs 










unclear if early intubation as opposed to BiPAP use would have resulted in better outcomes, 
especially for the patients who required intubation despite treatment with BiPAP. The other 
study assessed the outcomes in patients with SARS in one hospital that used BiPAP as initial 
ventilatory support compared with outcomes  in 13 hospitals in which only invasive 
mechanical ventilation was used.21 Patients in the hospital using BiPAP did not signif cantly 
differ from the patients in the hospitals not using any NIPPV in terms of demographic 
characteristics, co-morbidities and disease severity on admission apart from significantly 
higher Lactate dehydrogenase levels in the patients admitted to the NIPPV hospital. Patients 
in the NIPPV hospital had lower adjusted odds ratios (ORs) for intubation (OR 0. 36; 95% CI 
0.16 - 0.79) and death (OR 0. 24; 95% CI 0.08 -0.72) compared with patients in the hospitals 
only using mechanical ventilation. 
 
A systematic review identified 22 studies conducted on the use of NIPPV during the 2009 
influenza A pandemic caused by the swine influenza (H1N1) virus, of which the majority 
were case series and none were randomized trials.17 In a Spanish registry study of 685 
patients with H1N1 pneumonia 177 patients were treated with NIPPV (specific type of 
ventilation not specified), which was successful in 72 patients (41%); the remainder of 
patients required intubation. When NIPPV treatment failed, the delay in intubation was not 
associated with increased mortality compared with patients who were intubated without a 
trial of NIPPV (26.5% versus 24.2%, p <0.001).22 The lack of randomization introduces 
selection bias. Patients who were directly intubated w re likely sicker than those treated with 
NIPPV initially, and it is therefore unclear whether in comparable patients failure of NIPPV 











In summary, there is insufficient evidence about the effectiveness of NIPPV in AHRF due to 
viral pneumonia. Observational studies suggest that the use of NIPPV has the potential to 
reduce the need for intubation. It is unclear whether patients in whom NIPPV treatment fails 
would have had better outcomes if they would have been intubated earlier without a trial of 
NIPPV. Patients who can overcome severe COVID-19 without requiring intubation will 
benefit from avoiding sedation, inability to communicate, potential delirium and post-
traumatic stress disorder. Table 2 gives an overview of potential benefits and disadvantages 
of different breathing support strategies in acute respiratory failure. 
 
What are the benefits and harms of CPAP compared with oxygen administration and 
high flow nasal cannula in patients with AHRF due to COVID-19? 
High flow nasal cannula (HFNC) is an emerging therapy for AHRF that can warm and 
humidify gas, which can decrease airway inflammation, mprove mucus clearance and 
enhance patient comfort. HFNC can deliver a 21% to 100% fraction of inhaled oxygen at 
flow rates of up to 60 liters/min and generates a positive end-expiratory pressure which 
prevents alveolar collapse. 
 
Similar to NIPPV, recommendations about the use of HFNC in COVID-19 vary widely, and 
there is currently no available evidence to assess the effectiveness of HFNC compared with 
standard oxygen or CPAP. 
 
A European multicenter trial of 310 patients with AHRF (caused by pneumonia in 84% of the 
patients) found that treatment with HFNC, standard oxygen, or NIPPV did not result in 










than either standard oxygen or NIPPV.23 This could potentially suggest a role for HFNC in 
patients with AHRF due to COVID-19. 
 
What is the risk of viral transmission to healthcare professionals caring for COVID 
patients on NIPPV? 
Recommendations against the use of NIPPV and/or HFNC in patients with AHRF due to 
COVID are at least partially based on concerns about vir s spread in aerosols produced by 
these procedures. However, very little is known about the risk of viral transmission 
associated with different aerosol generating procedures. A systematic review found that 
tracheal intubation had a significantly higher risk of transmission of acute respiratory 
infections to healthcare professionals (OR 6.6, 95% confidence interval [CI] 2.3 to 18.9, 4 
cohort studies) than NIPPV (pooled OR 3.1, 95% CI 1.4 to 6.8, 2 cohort studies).24 A study 
that used laser smoke visualisation to assess dispers on distances during aerosol producing 
procedures using a human patient simulator found that the maximum exhaled air dispersion 
distance was greatest (100 cm) using a nasal cannul at an oxygen flow rate of 5litres/min 
while there was only negligible air dispersion with the use of CPAP via oronasal mask at a 
pressure of 20 cmH2O.
25  
 
The risk of viral transmission with NIPPV can be significantly reduced with the use of a filter 
on the expiratory circuit and the automatic measurement and quantification of a leak at the 
interface (which allows prompt leak correction and re uction of virus dispersion). Although 
intubation is associated with a high risk of viral tr nsmission, the risk can be reduced by 
techniques of apneic oxygenation and rapid sequence intubation with paralysis.  
Invasive mechanical ventilation has a reduced risk of viral transmission compared with 











In summary, there is insufficient evidence to determine whether CPAP and HFNC are 
associated with a higher viral transmission risk than standard oxygen delivered via nasal 
cannula or different mask types, especially when relatively high oxygen flow rates are used. 
The use of filters on the expiratory circuit of NIPPV may indeed result in lower viral 
transmission rates with NIPPV than with the use of standard oxygen or HFNC.  Precautions 
to minimize transmission from aerosol-generating procedures in COVID-19 patients are 
warranted, including the use of negative-pressure rooms, personal protective equipment 
including a respirator that ensures a level of protection equal or greater than N95/FFP2 and 
the use of viral/bacterial filters with any devices. 
 
Ongoing and future research 
On July 1, 2020, only 12 studies (including five randomized trials) that investigate NIPPV in 
COVID-19 were registered on ClinicalTrials.gov. This compares to a total of 2447 registered 
studies using the term “COVID”. The table in the supplement provides an overview of all 
identified studies and their characteristics. A US randomized trial assesses the effectiveness 
of CPAP treatment at home compared with no intervention in patients with presumed or 
confirmed COVID-19 who are sent home from the emergency room with mild pneumonia or 
respiratory illness. One randomized trial from the US and Sweden respectively compares 
helmet CPAP with HFNC; whereas an Italian trial compares helmet CPAP with no 
intervention. A French trial compares the effectiveness of standard oxygen, CPAP, HFNC, 
and invasive ventilation while also assessing the effectiveness of dexamethasone versus 












In the absence of sufficient evidence and pending tr al results, NIPPV should be considered 
as an alternative to early intubation, a d the type of NIPPV should be based on case-by-case 
decision making that takes into account a patient’s characteristics (e.g. the ability to 
independently move into a prone position) and co-morbidities (e.g. obstructive sleep apnea or 
chronic obstructive pulmonary disease). There is currently insufficient evidence to asses the 
effectiveness of HFNC compared with NIPPV in COVID-19. Safety concerns around aerosol 
spread of SARS-CoV-2 during NIPPV treatment make such trials difficult to conduct. 
Nevertheless, evidence from large well-conducted ran omized trials is urgently needed 
because future pandemics with other viral pneumonias are likely. These trials should address 
the effectiveness of NIPVV compared with early intubation and HFNC, and the risk of viral 
transmission to health care workers when patients are using different breathing support 
strategies. 
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Table 1. Guidance statements regarding the use of NIPPV in COVID-19 
 
Recommendation Organization Guidance Statement 
NIPPVi is 
recommended 
(at least in 
certain 
circumstances) 
Society of Critical Care 
Medicine/ European 
Society of Intensive Care 
Medicine, Surviving Sepsis 
Campaign, June 
20204 
For adults with COVID-19f and acute hypoxemic respiratory failure despite conventional oxygen 
therapy, we suggest using over conventional oxygen therapy (weak recommendation, low quality 
evidence). In adults with COVID-19f and acute hypoxemic respiratory failure, we suggest using 
HFNCg over NIPPVi (weak recommendation, low quality evidence). In adults with COVID-19f and 
acute hypoxemic respiratory failure, if HFNCg is not available and there is no urgent indication for 
endotracheal intubation, we suggest a trial of NIPPVi with close 
monitoring and short-interval assessment for worsening of respiratory failure (weak recommendation, 
very low-quality evidence).” 
 
National Health Service 
(NHS) 
United Kingdom, April 6, 
2020, Version 35 
“CPAPd is the preferred form of non-invasive ventilatory support in the management of the 
hypoxaemic COVID-19f patient. Its use does not replace invasive mechanical ventilation (IMVh), but 
early application may provide a bridge to IMVh.” 
“The use of NIVj (BiPAPc) should be reserved for those with hypercapnic acute on chronic ventilatory 
failure. “ 
 
Italian Thoracic Society 
(AIPO/ITS) and Italian 
Respiratory Society 
(SIP/IRS) 
March 8, 20206 
“NIVj can be used during isolation for confirmed cases.  Patients with previous respiratory diseases 
can benefit mainly from NIVj.  NIVj can prevent worsening in hypercapnic COPDe patients not at risk 
of pulmonary edema, who are without pneumonia, multiple organ failure or refractory hypoxemia.  Do 
not use NIVj in the Emergency Department in confirmed positive patients.  NIVj/CPAPd can be used in 
the post extubation phase of ARDSb.  NIVj/CPAPd can be used in less severe patients only if the 
patient is in a protected environment.”   
 
National Institutes of 
Health (NIH)7 
updated June 11, 2020 
“For adults with COVID-19f who are receiving supplemental oxygen, the COVID-19f Treatment 
Guidelines Panel (the Panel) recommends close monitoring for worsening respiratory status and 
recommends early intubation by an experienced practitioner in a controlled setting (AII). 
For adults with COVID-19f and acute hypoxemic respiratory failure despite conventional oxygen 
therapy, the Panel recommends high-flow nasal cannula (HFNCg) oxygen over noninvasive positive 
pressure ventilation (NIPPVi) (BI). 
In the absence of an indication for endotracheal intubation, the Panel recommends a closely 
monitored trial of NIPPVi for adults with COVID-19f and acute hypoxemic respiratory failure for whom 
HFNCg is not available (BIII).” 
 
 World Health Organization 
May 27, 2020, Interim 
“In selected patients with COVID-19f and mild ARDSb, a trial of HFNO [high-flow nasal oxygen], non-









Guidance8 (BiPAPc) may be used.” 
NIPPVi is not 
mentioned/has 
no role in COVID-
19f management 
American Thoracic Society 
April 3, 20209 
 
NIPPVi is not mentioned in the guidelines 
“For patients with refractory  hypoxemia due to progressive  COVID‐19f pneumonia (i.e., ARDSb), we 
suggest prone ventilation. For patients with refractory  hypoxemia due to progressive  COVID‐19f 
pneumonia (i.e., ARDSb),  we suggest that extracorporeal  membrane oxygenation (ECMO) be  
considered if prone ventilation fails.” 
 
Infectious Diseases 
Society of America 
Updated June25, 202010 
NIPPVi is not mentioned in the guidelines. There are no comments on any breathing support 
strategies in the guidelines. 
 
NIPPVi is not 
recommended 
Australian and New 
Zealand Intensive Care 
Society Australia, April15, 
2020, Version 211 
“Routine use of non-invasive ventilation (NIVj) is not recommended.  Current experience suggests 
that NIVj for COVID-19f hypoxic respiratory failure is associated with a high failure rate, delayed 
intubation, and possibly increased risk of aerosolization with poor mask fit.  Deteriorating patients 
should be considered for early endotracheal intubation and invasive mechanical ventilation.  If NIVj is 
appropriate for an alternate clinical presentation of COVID-19f (e.g. concomitant COPDe, APOa), this 
should be provided using similar precautions as for HFNO.” 
 
aAPO = acute pulmonary edema; bARDS = acute respiratory distress syndrome; cBiPAP = bilevel positive airway pressure; dCPAP = continuous positive 
airway pressure; eCOPD: chronic obstructive pulmonary disease; fCOVID-19 = Coronavirus disease 2019; gHFNC = high flow nasal cannula; hIMV = invasive 




















• Less invasive than intubation (A proportion of patients will 
survive without requiring intubation) 
• Avoids sedation, inability to communicate, potential delirium 
and post-traumatic stress disorder associated with intubation, 
if intubation can be avoided 
• May better alleviate dyspnea, work of breathing, hypoxia or 
hypercapnia compared to HFNCc and standard oxygen 
• May be used outside of the intensive care unit (for example, 
in a dedicated respiratory ward) 
• Provides a treatment option in patients with Do-Not-Intubate 
orders 
• Compared with intubation (and sedation), patients on 
NIPPVd may take larger tidal volumes and have an 
increased risk of subsequent lung injury 
• If NIPPVd fails, and intubation is required, the “delayed” 
intubation may be associated with a higher risk of 
complications due to a rushed procedure 
• Requires specialist nursing care, compared with HFNCc 
and standard oxygen 
• NIPPVd might be more aerosol producing (compared to 
HFNCc, standard oxygen, and invasive mechanical 
ventilation, apart from the high risk during intubation), 
though this risk can be reduced with viral filters, etc. 
• A tight fitting mask may be uncomfortable for patients, 
especially when used continuously for extended length of 
time; some patients cannot tolerate NIPPVd 




• Enables increased control of hypoxia, hypercapnia, and work 
of breathing compared with NIPPVd, HFNCc, and standard 
oxygen  
• Potentially avoids rushed intubation associated with risk of 
complications later compared with a failed  trial of NIPPVd 
• Once intubated with a closed respiratory circuit, the aerosol 
generating risk may be lower compared to NIPPVd 
• Treatment of choice when patient has significant inability to 
protect airway (e.g. due to severe encephalopathy) 
• Compared to NIPPVd or HFNCc, intubation with sedation 
may better facilitate patient undergoing certain procedures or 
transporting to a different medical facility (e.g. patient cannot 
lie flat for a computed tomography scan) 
 
• Requires specialist care in the intensive care unit 
(physician, nurses, respiratory therapists) 
• Often requires sedation, inability for patient to communicate 
and may have increased association with delirium and post-
traumatic stress disorder 
• May be associated with longer hospitalization and higher 
mortality compared to patients who have avoided intubation 
on NIPPVd  
• Risk of vocal cord damage, procedural hypotension, and 
other adverse effects directly associated with placement of 
an endotracheal tube 
• Potential for lung injury associated with positive end-
expiratory pressure 
• High risk of viral transmission during intubation (can be 
limited by techniques of apneic oxygenation and rapid 










procedures which require opening the circuit such as 
bronchoscopy or suctioning. 
• Compared with NIPPVd, it is unclear if early intubation is 
associated with improved patient outcomes. 
HFNCc 
• Compared to standard oxygen, HFNCc may be associated 
with improved hypoxia, improved hypercapnia (minor positive 
end-expiratory pressure support), and dyspnea 
• Compared to NIPPVd (and intubation), HFNCc is generally 
better tolerated and more comfortable, especially for 
extended continuous use. 
• Enables patient to speak, eat, and drink.  
• May even be more comfortable than high flow standard 
oxygen (HFNCc has heated humidifier)  
• Compared to NIPPVd, HFNCc may allow for improved 
mucociliary clearance 
• Provides a treatment option in patients with Do-Not-Intubate 
orders 
• May be used outside of the intensive care unit (for example, 
in a dedicated respiratory ward) 
• May require special nursing competency 
• Provides only minimal positive end-expiratory pressure 
compared to NIPPVd and invasive ventilation 
• Aerosol producing procedure and risk of viral transmission, 




• Does not require specialist nursing competency 
• Does not require a bed in the intensive care unit 
• More widely available than ventilators or BiPAPa machines 
• Provides a treatment option in patients with Do-Not-Intubate 
orders 
• Compared to NIPPVd, may be less aerosol producing 
• Is often less efficacious in improving hypoxia, hypercapnia, 
dyspnea, and work of breathing compared with HFNCc, 
NIPPVd, and intubation 
• May cause iatrogenic hypercapnic respiratory failure if the 
oxygen is not titrated and the patient is at risk of 
hypercapnia 
• High flow rates are aerosol producing 
 
aBiPAP = bilevel positive airway pressure; bCPAP = continuous positive airway pressure; cHFNC = high flow nasal cannula; dNIPPV = noninvasive positive 
pressure ventilation 
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